Browsing by Author "Satapathy, Prakasini"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    The resurgence of monkeypox: Epidemiology, clinical features, and public health implications in the post-smallpox eradication era
    (Elsevier, 2024-09-24) Singh, Parminder; Sridhar, Sathvik Belagodu; Shareef, Javedh; Talath, Sirajunisa; Mohapatra, Priyanka; Khatib, Mahalaqua Nazli; Ballal, Suhas; Kaur, Mandeep; Nathiya, Deepak; Sharma, Shilpa; Prasad, G. V. Siva; Sinha, Aashna; Varma, Amit; Bushi, Ganesh; Gaidhane, Abhay M.; Satapathy, Prakasini; Shabil, Muhammed; Sah, Renu; Al-Tawfiq, Jaffar A.; Sah, Ranjit; Rodriguez-Morales, Alfonso J.; Medicine, School of Medicine
    The recent global resurgence of Mpox (formerly monkeypox), primarily transmitted via close contact and respiratory droplets, highlights a significant shift in its epidemiology, particularly among men who have sex with men (MSM). This resurgence underscores the need for robust public health responses and improved surveillance. This comprehensive review of current literature focuses on recent outbreaks, virology, and available treatments. Epidemiological data were gathered from various international health reports and analysed to understand transmission dynamics and outbreak patterns. Mpox, characterised by symptoms like fever and rash, has shown variable clinical presentations, particularly among immunocompromised individuals. Recent outbreaks have prompted the development of new diagnostic methods and treatments, including antivirals like Tecovirimat and vaccines such as MVA-BN. Studies have demonstrated the effectiveness of these vaccines in preventing infection, which is crucial for outbreak containment. The global response to the Mpox resurgence requires integrated strategies combining vaccination, antiviral treatments, and public health policies tailored to high-risk populations. Future efforts should focus on vaccine distribution equity and enhancing diagnostic capabilities to effectively manage and mitigate the impact of Mpox.
  • Thumbnail Image
    Item
    The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review
    (Elsevier, 2023) Shamim, Muhammad Aaqib; Padhi, Bijaya Kumar; Satapathy, Prakasini; Veeramachaneni, Sai D.; Chatterjee, Chandrima; Tripathy, Snehasish; Akhtar, Naushaba; Pradhan, Anindita; Dwivedi, Pradeep; Mohanty, Aroop; Rodriguez-Morales, Alfonso J.; Sah, Ranjit; Al-Tammemi, Ala’a B.; Al-Tawfiq, Jaffar A.; Nowrouzi-Kia, Behdin; Chattu, Vijay Kumar; Medicine, School of Medicine
    Objectives: Human monkeypox virus (MPXV) infection is a recently declared public health emergency of international concern by the World Health Organization. Besides, there is scant literature available on the use of antivirals in MPXV infection. This systematic review compiles all evidence of various antivirals used on their efficacy and safety and summarizes their mechanisms of action. Methods: A review was done of all original studies mentioning individual patient data on the use of antivirals in patients with MPXV infection. Results: Of the total 487 non-duplicate studies, 18 studies with 71 individuals were included. Tecovirimat was used in 61 individuals, followed by cidofovir in seven and brincidofovir (BCV) in three individuals. Topical trifluridine was used in four ophthalmic cases in addition to tecovirimat. Of the total, 59 (83.1%) were reported to have complete resolution of symptoms; one was experiencing waxing and waning of symptoms, only one (1.8%) had died, and the others were having a resolution of symptoms. The death was thought unrelated to tecovirimat. Elevated hepatic panels were reported among all individuals treated with BCV (leading to treatment discontinuation) and five treated with tecovirimat. Conclusion: Tecovirimat is the most used and has proven beneficial in several aggravating cases. No major safety concerns were detected upon its use. Topical trifluridine was used as an adjuvant treatment option along with tecovirimat. BCV and cidofovir were seldom used, with the latter often being used due to the unavailability of tecovirimat. BCV was associated with treatment discontinuation due to adverse events.